Lauren B. Ostermann

Lauren B. Ostermann

Auto-generated profile, based on publicly available information

Lauren B. Ostermann

Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2023 in Leukemia
Verified
Journal Article
Closed access
PDF file
HAHiroki Akiyama
Hiroki Akiyama
RZRan Zhao
Ran Zhao
LOLauren B. Ostermann
Lauren B. Ostermann
ZLZiyi Li
Ziyi Li
MTMatthew Tcheng
Matthew Tcheng
JIJo Ishizawa
Jo Ishizawa

28 October 2021 in Blood
Verified
Journal Article
Open access
PDF file
BCBing Z. Carter
Bing Z. Carter
WTWenjing Tao
Wenjing Tao
PMPo Yee Mak
Po Yee Mak
LOLauren B. Ostermann
Lauren B. Ostermann
DMDuncan Mak
Duncan Mak
MAMichael Andreeff
Michael Andreeff

1 December 2023 in Science Advances
Verified
Journal Article
Open access
YNYuki Nishida
Yuki Nishida
JIJo Ishizawa
Jo Ishizawa
EAEdward Ayoub
Edward Ayoub
RMRafael Heinz Montoya
Rafael Heinz Montoya
LOLauren B. Ostermann
Lauren B. Ostermann
MAMichael Andreeff
Michael Andreeff
The tumor suppressor TP53 is frequently inactivated in a mutation-independent manner in cancers and is reactivated by inhibiting its negative regulators. We here cotarget MDM2 and the nuclear exporter XPO1 to maximize transcriptional activity of p53. MDM2/XPO1 inhibition accumulated nuclear p53 and elicited a 25- to 60-fold increase of its transcriptional targets. TP53 regulates MYC , and MDM2/XPO1 inhibition disrupted the c-MYC–regulated transcriptome, resulting in the synergistic induction of apoptosis in acute myeloid leukemia (AML). Unexpectedly, venetoclax-resistant AMLs express high levels of c-MYC and are vulnerable to MDM2/XPO1 inhibition in vivo. However, AML cells persisting after MDM2/XPO1 inhibition exhibit a quiescence- and stress response–associated phenotype. Venetoclax overcomes that resistance, as shown by single-cell mass cytometry. The triple inhibition of MDM2, XPO1, and BCL2 was highly effective against venetoclax-resistant AML in vivo. Our results propose a novel, highly translatable therapeutic approach leveraging p53 reactivation to overcome nongenetic, stress-adapted venetoclax resistance.

24 April 2023 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
BCBing Z. Carter
Bing Z. Carter
PMPo Yee Mak
Po Yee Mak
WTWenjing Tao
Wenjing Tao
EAEdward Ayoub
Edward Ayoub
LOLauren B. Ostermann
Lauren B. Ostermann
MAMichael Andreeff
Michael Andreeff
TP53-mutant acute myeloid leukemia (AML) respond poorly to currently available treatments, including venetoclax-based drug combinations and pose a major therapeutic challenge. Analyses of RNA sequencing and reverse phase protein array datasets revealed significantly lower BAX RNA and protein levels in TP53-mutant compared to TP53–wild-type (WT) AML, a finding confirmed in isogenic CRISPR-generated TP53-knockout and -mutant AML. The response to either BCL-2 (venetoclax) or MCL-1 (AMG176) inhibition was BAX-dependent and much reduced in TP53-mutant compared to TP53-WT cells, while the combination of two BH3 mimetics effectively activated BAX, circumventing survival mechanisms in cells treated with either BH3 mimetic, and synergistically induced cell death in TP53-mutant AML and stem/progenitor cells. The BH3 mimetic–driven stress response and cell death patterns after dual inhibition were largely independent of TP53 status and affected by apoptosis induction. Co-targeting, but not individual targeting of BCL-2 and MCL-1 in mice xenografted with TP53-WT and TP53-R248W Molm13 cells suppressed both TP53-WT and TP53-mutant cell growth and significantly prolonged survival. Our results demonstrate that co-targeting BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance to individual BH3 mimetics in TP53-mutant cells, thus shifting cell fate from survival to death in TP53-deficient and -mutant AML. This concept warrants clinical evaluation.

21 September 2023 in Blood
Verified
Journal Article
Open access
PDF file
BCBing Z Carter
Bing Z Carter
PMPo Yee Yee Mak
Po Yee Yee Mak
MMMuharrem Muftuoglu
Muharrem Muftuoglu
WTWenjing Tao
Wenjing Tao
KBKe Baozhen
Ke Baozhen
MAMichael Andreeff
Michael Andreeff
TP 53-mutant acute myeloid leukemia (AML) remains the ultimate therapeutic challenge. Epichaperomes, formed in malignant cells, consist of heat shock protein 90 (HSP90) and associated proteins that support the maturation, activity, and stability of oncogenic kinases and transcription factors including mutant p53. High-throughput drug screening identified HSP90 inhibitors as top hits in isogenic TP53–wild-type (WT) and -mutant AML cells. We detected epichaperomes in AML cells and stem/progenitor cells with TP53 mutations but not in healthy bone marrow (BM) cells. Hence, we investigated the therapeutic potential of specifically targeting epichaperomes with PU-H71 in TP53-mutant AML based on its preferred binding to HSP90 within epichaperomes. PU-H71 effectively suppressed cell intrinsic stress responses and killed AML cells, primarily by inducing apoptosis; targeted TP53-mutant stem/progenitor cells; and prolonged survival of TP53-mutant AML xenograft and patient-derived xenograft models, but it had minimal effects on healthy human BM CD34+ cells or on murine hematopoiesis. PU-H71 decreased MCL-1 and multiple signal proteins, increased proapoptotic Bcl-2-like protein 11 levels, and synergized with BCL-2 inhibitor venetoclax in TP53-mutant AML. Notably, PU-H71 effectively killed TP53-WT and -mutant cells in isogenic TP53-WT/TP53-R248W Molm13 cell mixtures, whereas MDM2 or BCL-2 inhibition only reduced TP53-WT but favored the outgrowth of TP53-mutant cells. Venetoclax enhanced the killing of both TP53-WT and -mutant cells by PU-H71 in a xenograft model. Our data suggest that epichaperome function is essential for TP53-mutant AML growth and survival and that its inhibition targets mutant AML and stem/progenitor cells, enhances venetoclax activity, and prevents the outgrowth of venetoclax-resistant TP53-mutant AML clones. These concepts warrant clinical evaluation.

21 April 2023 in Leukemia
Verified
Journal Article
Open access
PDF file
YJYannan Jia
Yannan Jia
WZWeiguo Zhang
Weiguo Zhang
MBMahesh Basyal
Mahesh Basyal
KCKyung Hee Chang
Kyung Hee Chang
LOLauren Ostermann
Lauren Ostermann
MAMichael Andreeff
Michael Andreeff